Compositions and Methods for Diagnosing, Treating, and Preventing Prostate Conditions
Musc Foundation for Research Development
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 3 of these applications claim priority to application PCT/US2008/051168, filed Jan 16, 2008. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 8,735,365 | Targeting PAX2 for the Induction of DEFB1-MEDIATED Tumor Immunity and Cancer Therapy In force · Medium confidence | Musc Foundation for Research Development | In force | Medium confidence | ||
| US 7,964,577 | Targeting PAX2 for the Induction of DEFB1-MEDIATED Tumor Immunity and Cancer Therapy In force · High confidence | Phigenix, Inc. | In force | High confidence | ||
| US 8,623,617 | Detecting PAX2 for the Diagnosis of Breast Cancer In force (reinstated) · Medium confidence | Musc Foundation for Research Development | In force (reinstated) | Medium confidence | ||
| US 8,722,367 | Detecting PAX2 for the Diagnosis of Breast Cancer In force · Medium confidence | Musc Foundation for Research Development | In force | Medium confidence | ||
| US 8,088,603 | Compositions and Methods for Diagnosing, Treating, and Preventing Prostate Conditions In force · High confidence | Musc Foundation for Research Development | In force | High confidence | ||
| US 8,318,692 | Targeting PAX2 for the Induction of DEFB1-MEDIATED Tumor Immunity and Cancer Therapy Lapsed Nov 27, 2024 on the fee record High confidence | Musc Foundation for Research Development | Lapsed Nov 27, 2024 on the fee record | High confidence | ||
| US 8,431,546 | Targeting PAX2 for the Induction of DEFB1-MEDIATED Tumor Immunity and Cancer Therapy Lapsed Apr 30, 2025 on the fee record High confidence | Musc Foundation for Research Development | Lapsed Apr 30, 2025 on the fee record | High confidence | ||
| US 8,445,444 | Compositions and Methods for Diagnosing, Treating, and Preventing Prostate Conditions Lapsed May 21, 2025 on the fee record Medium confidence | Musc Foundation for Research Development | Lapsed May 21, 2025 on the fee record | Medium confidence | ||
| US 8,461,101 | Targeting PAX2 for the Treatment of Breast Cancer Lapsed Jun 11, 2025 on the fee record High confidence | Musc Foundation for Research Development | Lapsed Jun 11, 2025 on the fee record | High confidence | ||
| US 8,461,126 | Targeting EN2, PAX2, And/Or DEFB1 for Treatment of Prostate Conditions Lapsed Jun 11, 2025 on the fee record High confidence | Musc Foundation for Research Development | Lapsed Jun 11, 2025 on the fee record | High confidence | ||
| 16 more patents in this group · Pro | ||||||
10 of 26 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Pro members see all 26, including 10 expired and 4 expiring within the 18 months from Nov 18, 2026.
4 of these are in force and held by Musc Foundation for Research Development.
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.